Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

Date Added
August 1st, 2025
PRO Number
Pro00143821
Researcher
Eric Meissner

List of Studies


Keywords
Infectious Diseases
Summary

The purpose of this clinical research study is to evaluate the safety and effectiveness of the investigational drug called bemnifosbuvir-ruzasvir (BEM/RZR) in comparison to the FDA approved comparator drug in treating chronic Hepatitis C Virus (HCV) infection.

Institution
MUSC
Recruitment Contact
Jamila Williams
(843) 792-1088
keithja@musc.edu



-- OR --